VU 0240551KCC2 inhibitor CAS# 893990-34-6 |
- FLAG tag Peptide
Catalog No.:BCC2562
CAS No.:98849-88-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 893990-34-6 | SDF | Download SDF |
| PubChem ID | 7211972 | Appearance | Powder |
| Formula | C16H14N4OS2 | M.Wt | 342.44 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (146.01 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-(4-methyl-1,3-thiazol-2-yl)-2-(6-phenylpyridazin-3-yl)sulfanylacetamide | ||
| SMILES | CC1=CSC(=N1)NC(=O)CSC2=NN=C(C=C2)C3=CC=CC=C3 | ||
| Standard InChIKey | WJRWSLORVIHRNX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H14N4OS2/c1-11-9-23-16(17-11)18-14(21)10-22-15-8-7-13(19-20-15)12-5-3-2-4-6-12/h2-9H,10H2,1H3,(H,17,18,21) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Inhibitor of the neuronal K-Cl cotransporter, KCC2 (IC50 = 560 nM for K+ uptake assay in KCC2-overexpressing cells). Exhibits selectivity over the Na-K-2Cl cotransporter, NKCCl. Also inhibits hERG and L-type Ca2+ channels. |
VU 0240551 Dilution Calculator
VU 0240551 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9202 mL | 14.6011 mL | 29.2022 mL | 58.4044 mL | 73.0055 mL |
| 5 mM | 0.584 mL | 2.9202 mL | 5.8404 mL | 11.6809 mL | 14.6011 mL |
| 10 mM | 0.292 mL | 1.4601 mL | 2.9202 mL | 5.8404 mL | 7.3005 mL |
| 50 mM | 0.0584 mL | 0.292 mL | 0.584 mL | 1.1681 mL | 1.4601 mL |
| 100 mM | 0.0292 mL | 0.146 mL | 0.292 mL | 0.584 mL | 0.7301 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
VU 0240551 is a small-molecule inhibitor of KCC2 with IC50 value of 560nM [1].
KCC2 is one of the K+-Cl+ cotransporters and is exclusively expressed in CNS neurons. KCC2 transports Cl+ in an electroneutral way and plays a key role in maintaining intracellular Cl+ concentration in neurons. VU 0240551 is screened out from a library of 234,000 small molecules by tested in HEK293 cells overexpressing KCC2. VU 0240551 potently inhibits KCC2 with IC50 value of 560nM while shows minimal effect on NKCC1. VU 0240551 at concentration of 5μM inhibits 12.9% activity of NKCC1. Besides that, VU 0240551 significantly inhibits KCC2-mediated K+ uptake at concentration of 10μM. VU 0240551 is also found to inhibit KCC3 in the micromolar range. Moreover, when treated with some other GPCRs, ion channels and transporters, VU 0240551 exerts significant effects on Adenosine A1 and A3 receptors, L- type Ca2+ channel and K+ channel hERG [1, 2].
References:
[1] Delpire E, Days E, Lewis L M, et al. Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proceedings of the National Academy of Sciences, 2009, 106(13): 5383-5388.
[2] Friauf E, Rust M B, Schulenborg T, et al. Chloride cotransporters, chloride homeostasis, and synaptic inhibition in the developing auditory system. Hearing research, 2011, 279(1): 96-110.
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
- PF 945863
Catalog No.:BCC6172
CAS No.:893556-85-9
- Riligustilide
Catalog No.:BCC9136
CAS No.:89354-45-0
- Chiisanoside
Catalog No.:BCN2712
CAS No.:89354-01-8
- ICI 174,864
Catalog No.:BCC5675
CAS No.:89352-67-0
- 3,4-O,O-Methylene-(+)-catechin
Catalog No.:BCN7962
CAS No.:89329-14-6
- 2,4-Dihydroxy-3-nitropyridine
Catalog No.:BCC8499
CAS No.:89282-12-2
- MF63
Catalog No.:BCC1744
CAS No.:892549-43-8
- 2-(Chloromethyl)-4-(4-nitrophenyl)-1,3-thiazole
Catalog No.:BCC8372
CAS No.:89250-26-0
- AZD 3988
Catalog No.:BCC5621
CAS No.:892489-52-0
- Manidipine 2HCl
Catalog No.:BCC4405
CAS No.:89226-75-5
- Manidipine
Catalog No.:BCC4404
CAS No.:89226-50-6
- LDN 212320
Catalog No.:BCC6361
CAS No.:894002-50-7
- Raddeanin A
Catalog No.:BCN1084
CAS No.:89412-79-3
- STF-118804
Catalog No.:BCC4850
CAS No.:894187-61-2
- [D-Trp7,9,10]-Substance P
Catalog No.:BCC7202
CAS No.:89430-38-6
- DMOG
Catalog No.:BCC2433
CAS No.:89464-63-1
- BIBF 1202
Catalog No.:BCC5298
CAS No.:894783-71-2
- ST 2825
Catalog No.:BCC1967
CAS No.:894787-30-5
- TCS JNK 6o
Catalog No.:BCC7607
CAS No.:894804-07-0
- Picrasinol B
Catalog No.:BCN4440
CAS No.:89498-91-9
- Methylneoquassin
Catalog No.:BCN3121
CAS No.:89498-93-1
- SC 144
Catalog No.:BCC1171
CAS No.:895158-95-9
- Flumatinib mesylate
Catalog No.:BCC3970
CAS No.:895519-91-2
[Lessons learned from the evacuation of the VU University Medical Centre after flooding].[Pubmed:28224872]
Ned Tijdschr Geneeskd. 2017;161:D861.
On 8 September 2015, flooding of the lower floors of the VU University Medical Center in Amsterdam caused serious damage to many vital technical services, such as water and power supplies. The decision was made to completely evacuate the university hospital. This paper describes the chronology and events of that day and shares a number of important lessons that were learned, in order to help readers to optimise crisis organisation in their own institutions. A serious situation or disaster can never be standardised in protocols or manuals; flexibility, improvisation and confidence in one another's expertise and commitment are therefore essential.
Effects of VU0240551, a novel KCC2 antagonist, and DIDS on chloride homeostasis of neocortical neurons from rats and humans.[Pubmed:25086309]
Neuroscience. 2014 Sep 26;277:831-41.
The normal function of GABAA receptor-mediated inhibition is governed by several factors, including release of GABA, subunit composition and density of the receptors and in particular by the appropriate ionic gradient. In the human epileptogenic neocortex an impaired chloride (Cl(-)) gradient has been proposed, due to decreases of potassium-coupled chloride transport (KCC2) and voltage-gated Cl(-) channels (ClC). Regarding sodium- and potassium-coupled Cl(-) transport (NKCC1) both up- and downregulations have been proposed. We investigated changes of Cl(-) homeostasis of human and rat neocortical neurons (layer 2/3) with intracellular recordings and iontophoretic Cl(-) loading employing selective compounds. After cessation of iontophoresis, the IPSPA amplitudes of rat neurons recovered with a time constant (taurec) of 6.5s (n=21). In human neurons, taurec averaged 17.8s (n=36; 23 resections). Application of the novel KCC2 blocker VU0240551 (1 muM) caused in rat neurons a reversible prolongation of taurec from 5.7 to 8.1s (n=11), corresponding to a VU0240551-sensitive Cl(-) transport rate (1/Deltataurec) of 0.0504s(-1). In human neurons, taurec increased on application of 1muM VU0240551, on average from 15.1 to 20.3s (n=17). The human neurons comprised two subgroups with different taurec when segregated according to a border given by the mean+2s.d. of rat neurons. In one group, taurec averaged 8.7s (n=6) and reversibly increased to 14.6s in the presence of 1muM VU0240551, corresponding to a Cl(-) transport rate of 0.0504s(-1). The other group had an average taurec of 18.5s which increased in the presence of 1muM VU0240551 to 23.3s (n=11), indicating a much smaller rate (0.0151s(-1)). Addition of DIDS, a presumed blocker of anion exchanger (AE), increased the taurec of rat neurons from 7.5 to 8.8s (n=6) corresponding to a DIDS-sensitive rate of 0.0185s(-1). In human neurons, DIDS increased taurec from 23.3 to 50.7s (n=7), corresponding to a DIDS-sensitive rate of 0.0200s(-1). These data suggest a greatly reduced KCC2-mediated transport rate in most of the human neurons. The two subgroups observed in human tissue indicate a considerable variability of Cl(-) transport within a given tissue from almost normal to greatly impeded, predominated by a decline of KCC2 whereas AE is unaltered.
Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe.[Pubmed:22727639]
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4532-5.
Further chemical optimization of the MLSCN/MLPCN probe ML077 (KCC2 IC(50)=537 nM) proved to be challenging as the effort was characterized by steep SAR. However, a multi-dimensional iterative parallel synthesis approach proved productive. Herein we report the discovery and SAR of an improved novel antagonist (VU0463271) of the neuronal-specific potassium-chloride cotransporter 2 (KCC2), with an IC(50) of 61 nM and >100-fold selectivity versus the closely related Na-K-2Cl cotransporter 1 (NKCC1) and no activity in a larger panel of GPCRs, ion channels and transporters.
Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2.[Pubmed:19279215]
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5383-8.
KCC2, a neuronal-specific K-Cl cotransporter, plays a major role in maintaining intracellular Cl(-) concentration in neurons below its electrochemical equilibrium potential, thus favoring robust GABA hyperpolarizing or inhibitory responses. The pharmacology of the K-Cl cotransporter is dominated by loop diuretics such as furosemide and bumetanide, molecules used in clinical medicine because they inhibit the loop of Henle Na-K-2Cl cotransporter with much higher affinity. To identify molecules that affect KCC2 activity, we developed a fluorescence-based assay suitable for high-throughput screening (HTS) and used the assay to screen a library of 234,000 small molecules. We identified a large number of molecules that either decrease or increase the activity of the cotransporter. Here, we report the characterization of a small number of inhibitors, some of which inhibit KCC2 activity in the submicomolar range without substantially affecting NKCC1 activity. Using medicinal chemistry, we synthesized a number of variants, tested their effect on KCC2 function, and provide an analysis of structure/activity relationships. We also used one of the compounds to demonstrate competitive inhibition in regard to external [K(+)] versus noncompetitive inhibition in respect to external [Cl(-)].
